Taiwan · Delayed Price · Currency is TWD Sunny Pharmtech Statistics
Total Valuation
Sunny Pharmtech has a market cap or net worth of TWD 1.81 billion. The enterprise value is 2.03 billion.
| Market Cap | 1.81B |
| Enterprise Value | 2.03B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sunny Pharmtech has 148.84 million shares outstanding. The number of shares has increased by 2.33% in one year.
| Current Share Class | 148.84M |
| Shares Outstanding | 148.84M |
| Shares Change (YoY) | +2.33% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 17.86% |
| Owned by Institutions (%) | 3.56% |
| Float | 105.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.75 |
| PB Ratio | 2.21 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 0.38.
| Current Ratio | 1.92 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.67 |
| Interest Coverage | -30.46 |
Financial Efficiency
Return on equity (ROE) is -37.94% and return on invested capital (ROIC) is -17.76%.
| Return on Equity (ROE) | -37.94% |
| Return on Assets (ROA) | -15.55% |
| Return on Invested Capital (ROIC) | -17.76% |
| Return on Capital Employed (ROCE) | -29.71% |
| Weighted Average Cost of Capital (WACC) | 5.44% |
| Revenue Per Employee | 1.48M |
| Profits Per Employee | -2.06M |
| Employee Count | 158 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.48% in the last 52 weeks. The beta is 0.29, so Sunny Pharmtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -34.48% |
| 50-Day Moving Average | 12.83 |
| 200-Day Moving Average | 14.11 |
| Relative Strength Index (RSI) | 47.20 |
| Average Volume (20 Days) | 254,447 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sunny Pharmtech had revenue of TWD 233.36 million and -325.13 million in losses. Loss per share was -2.14.
| Revenue | 233.36M |
| Gross Profit | 36.96M |
| Operating Income | -350.09M |
| Pretax Income | -325.13M |
| Net Income | -325.13M |
| EBITDA | -231.60M |
| EBIT | -350.09M |
| Loss Per Share | -2.14 |
Balance Sheet
The company has 94.41 million in cash and 311.67 million in debt, with a net cash position of -217.26 million or -1.46 per share.
| Cash & Cash Equivalents | 94.41M |
| Total Debt | 311.67M |
| Net Cash | -217.26M |
| Net Cash Per Share | -1.46 |
| Equity (Book Value) | 819.27M |
| Book Value Per Share | 5.31 |
| Working Capital | 131.26M |
Cash Flow
In the last 12 months, operating cash flow was -153.58 million and capital expenditures -33.13 million, giving a free cash flow of -186.71 million.
| Operating Cash Flow | -153.58M |
| Capital Expenditures | -33.13M |
| Depreciation & Amortization | 118.49M |
| Net Borrowing | -109.00M |
| Free Cash Flow | -186.71M |
| FCF Per Share | -1.25 |
Margins
Gross margin is 15.84%, with operating and profit margins of -150.02% and -139.33%.
| Gross Margin | 15.84% |
| Operating Margin | -150.02% |
| Pretax Margin | -139.33% |
| Profit Margin | -139.33% |
| EBITDA Margin | -99.25% |
| EBIT Margin | -150.02% |
| FCF Margin | n/a |
Dividends & Yields
Sunny Pharmtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.33% |
| Shareholder Yield | -2.33% |
| Earnings Yield | -17.98% |
| FCF Yield | -10.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |